Infliximab  versus  intravenous pulse methylprednisolone treatment for immunoglobulin-resistant kawasaki disease: a systematic review and adjusted indirect comparison metaanalysis

Han Chan; Han Chan; Yuhao Wang; Yuhao Wang; Junli Yan; Junli Yan; Gaofu Zhang; Gaofu Zhang; Mo Wang; Mo Wang; Haiping Yang; Haiping Yang; Qiu Li; Qiu Li

doi:10.18632/oncotarget.23245

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 12/14/2017.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Infliximab versus intravenous pulse methylprednisolone treatment for immunoglobulin-resistant kawasaki disease: a systematic review and adjusted indirect comparison metaanalysis

Han Chan, Han Chan, Yuhao Wang, Yuhao Wang, Junli Yan, Junli Yan, Gaofu Zhang, Gaofu Zhang, Mo Wang, Mo Wang, Haiping Yang _, Haiping Yang, Qiu Li and Qiu Li _

Han Chan1,2,*,Yuhao Wang1,*, Junli Yan1,2,*, Gaofu Zhang1,2, Mo Wang1,2, Haiping Yang1,2 and Qiu Li1,2

1 Department of Nephrology, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

2 Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China

* These authors have contributed equally to this work

Correspondence to:

Haiping Yang, email: [email protected]

Qiu Li, email: [email protected]

Keywords: infliximab; methylprednisolone; intravenous immunoglobulin; mucocutaneous lymph node syndrome

Received: September 01, 2017 Accepted: November 16, 2017 Epub: December 14, 2017

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23245

Publication Alerts

Withdrawal Notice

Research Papers:

Infliximab versus intravenous pulse methylprednisolone treatment for immunoglobulin-resistant kawasaki disease: a systematic review and adjusted indirect comparison metaanalysis